Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
730
datasets available to search
ShareScore release 0.9.0
Dataset results
730 results for “rhinitis”
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
ClinicalTrials.gov study NCT00296491. IPD Sharing: YES. Countries: 4. Publications: 1.
Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis
ClinicalTrials.gov study NCT07323888. IPD Sharing: NO. Countries: 1. Publications: 4.
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
ClinicalTrials.gov study NCT01134705. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
ClinicalTrials.gov study NCT00953147. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis
ClinicalTrials.gov study NCT00609674. IPD Sharing: YES. Countries: 7. Publications: 1.
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
ClinicalTrials.gov study NCT02631551. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
ClinicalTrials.gov study NCT01940146. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis
ClinicalTrials.gov study NCT00730756. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (CLARITY)
ClinicalTrials.gov study NCT05324397. IPD Sharing: NO. Countries: 1. Publications: 2.
Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis
ClinicalTrials.gov study NCT07317960. IPD Sharing: YES. Countries: 1. Publications: 1.
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
ClinicalTrials.gov study NCT01024608. IPD Sharing: Not stated. Countries: 1. Publications: 1.
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
ClinicalTrials.gov study NCT01794741. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis
ClinicalTrials.gov study NCT00361439. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?
ClinicalTrials.gov study NCT00618332. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis
ClinicalTrials.gov study NCT02288156. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Herbal Treatment for Perennial Allergic Rhinitis
ClinicalTrials.gov study NCT00456755. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
ClinicalTrials.gov study NCT00619801. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
ClinicalTrials.gov study NCT01861522. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A cost-effectiveness analysis of second-generation antihistamine 1 receptor blockers and Japanese kampo shoseiryuto for treatment of perennial allergic rhinitis in outpatient settings in Japan
<p><strong><span>Background: </span></strong><span>Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are used commonly </span><span>for its</span><span> treatment, but it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese kampo shoseiryuto, which has been traditionally prescribed to treat PAR in Japan, remain poorly understood.</span></p> <p><strong><span>Objectives: </span></strong><span>This study aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer's perspective, using a base-case analysis.</span></p> <p><strong><span>Methods: </span></strong><span>The current study entailed identification of the most cost-effective of the six SGAs (</span><span>bepotastine 10 mg, cetirizine 10 mg, ebastine 10 mg, </span><span>epinastine 20</span><span> mg, loratadine 10 mg, and olopatadine 5 mg) and shoseiryuto, whose clinical effectiveness were evaluated using the overall improvement rate. </span><span>T</span><span>he time horizon</span><span> was 14 days. Costs were identified based on the Medical Fee Index in 2020.</span></p> <p><strong><span>Key findings: </span></strong><span>Overall, bepotastine 10 mg, cetirizine 10 mg, </span><span>ebastine </span><span>10 mg, and loratadine 10 mg were found to be cost-effective. Shoseiryuto was less cost-effective than ebastine 10 mg (dominated). Ebastine 10 mg was found to be the most cost-effective based on deterministic and probabilistic sensitivity analyses.</span></p> <p><strong><span>Conclusions: </span></strong><span>Ebastine 10 mg was found to be the most cost-effective treatment strategy for PAR among the agents evaluated in this study</span><span>. This insight might help </span><span>in creating an appropriate formulary for the treatment of PAR in hospitals and communities.</span></p>
Nasal nitric oxide is a controversial biomarker for the diagnosis of allergic rhinitis
<p>Data set of nNO measurements in subjects reporting rhinitis</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.